EDWARDS LIFESCIENCES CORPORATION Funds and ETFs Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.14 USD | -2.00% |
|
-2.04% | +13.03% |
| 23/05 | Some of the biggest splits in Corporate America | RE |
| 22/05 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
ETFs positioned on Edwards Lifesciences Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 42 M€ | -0.77% | - | |
| 2.34% | 17 M€ | +6.09% | - | |
| 2.13% | 6 M€ | 0.00% | - | |
| 1.17% | 224 M€ | +2.30% | - | |
| 1.17% | 24 M€ | 0.00% | - | |
| 1.17% | 26 M€ | +0.10% | - | |
| 1.11% | 14 M€ | -5.07% | ||
| 1.06% | 2 M€ | 0.00% | ||
| 0.97% | 1 M€ | +2.21% | - | |
| 0.94% | 4,592 M€ | -.--% | ||
| 0.89% | 37 M€ | -.--% | ||
| 0.73% | 9 M€ | -.--% | - | |
| 0.52% | 1 M€ | +16.32% | ||
| 0.46% | 2 M€ | +20.44% | - | |
| 0.44% | 5 M€ | -72.95% | - | |
| 0.42% | 3,859 M€ | +18.82% | - | |
| 0.42% | 469 M€ | -2.05% | ||
| 0.36% | 8 M€ | +3.41% | ||
| 0.36% | 2,383 M€ | +12.69% | ||
| 0.34% | 36 M€ | +22.19% | ||
| 0.33% | 50 M€ | +8.95% | ||
| 0.33% | 25 M€ | +3.23% | - | |
| 0.30% | 727 M€ | +7.40% | ||
| 0.30% | 219 M€ | +17.17% | - | |
| 0.30% | 1,448 M€ | -.--% | - | |
| 0.25% | 264 M€ | -.--% | - | |
| 0.24% | 187 M€ | +10.12% | - | |
| 0.24% | 477 M€ | +11.27% | ||
| 0.24% | 330 M€ | -.--% | ||
| 0.23% | 2 M€ | +14.69% | - | |
| 0.23% | 8 M€ | +5.41% | - | |
| 0.23% | 744 M€ | +8.16% | ||
| 0.21% | 276 M€ | +11.40% | - |
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
25/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
87.89
USD
Average target price
96.55
USD
Spread / Average Target
+9.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.03% | 52.96B | |
| +6.38% | 215B | |
| +9.85% | 187B | |
| +18.18% | 143B | |
| +29.55% | 110B | |
| +1.48% | 64.68B | |
| -0.16% | 49.84B | |
| -5.77% | 38.32B | |
| +0.61% | 35.86B | |
| +19.70% | 30.75B |
- Stock Market
- Equities
- EW Stock
- Funds and ETFs Edwards Lifesciences Corporation
